{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:40:38Z","timestamp":1790458838286,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ijpharm.2016.05.064","type":"journal-article","created":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T06:24:42Z","timestamp":1464762282000},"page":"279-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas"],"prefix":"10.1016","volume":"509","author":[{"given":"Guillaume","family":"Bougu\u00e9on","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lagarce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Pailhori\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bastiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Vrignaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijpharm.2016.05.064_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jdv.12665","article-title":"Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"29","author":"Balestri","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ijpharm.2016.05.064_bib0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ijpharm.2016.05.064_bib0015","doi-asserted-by":"crossref","first-page":"S668","DOI":"10.1016\/j.annder.2015.10.515","article-title":"Traitement des angiofibromes de la scl\u00e9rose tub\u00e9reuse de Bourneville par des pr\u00e9parations topiques \u00e0 base de sirolimus: \u00e9tat des lieux de la pr\u00e9paration en France et revue de la litt\u00e9rature","volume":"142","author":"Bougu\u00e9on","year":"2015","journal-title":"Ann. Dermatol. Venereol."},{"issue":"7","key":"10.1016\/j.ijpharm.2016.05.064_bib0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","article-title":"Topical rapamycin a novel approach to facial angiofibromas in tuberous sclerosis","volume":"146","author":"Haemel","year":"2010","journal-title":"Arch. Dermatol."},{"issue":"2","key":"10.1016\/j.ijpharm.2016.05.064_bib0025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2133.2008.08677.x","article-title":"The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis","volume":"159","author":"Hofbauer","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ijpharm.2016.05.064_bib0030","unstructured":"International Conference on Harmonisation. Q2 (R1): Validation of Analytical Procedures: Text and Methodology, 2015, 6\u201312."},{"key":"10.1016\/j.ijpharm.2016.05.064_bib0035","article-title":"Tuberous sclerosis complex: an update for dermatologists","volume":"17","author":"Jacks","year":"2015","journal-title":"Pediatr. Dermatol."},{"issue":"1","key":"10.1016\/j.ijpharm.2016.05.064_bib0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/2229-5178.105488","article-title":"Topical rapamycin (sirolimus) for facial angiofibromas","volume":"4","author":"Madke","year":"2013","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.ijpharm.2016.05.064_bib0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0928-0987(99)00075-5","article-title":"Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations","volume":"9","author":"Mura","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.05.064_bib0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000357033","article-title":"Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy","volume":"228","author":"Park","year":"2014","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.ijpharm.2016.05.064_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-5945-8-1","article-title":"Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model","volume":"8","author":"Rauktys","year":"2008","journal-title":"BMC Dermatol."},{"issue":"3","key":"10.1016\/j.ijpharm.2016.05.064_bib0060","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpba.2006.02.009","article-title":"Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC","volume":"41","author":"Ricciutelli","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijpharm.2016.05.064_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajd.12125","article-title":"Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions","volume":"55","author":"Tu","year":"2014","journal-title":"Australas. J. Dermatol."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316304549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316304549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T14:23:36Z","timestamp":1536675816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517316304549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":13,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0378517316304549"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.05.064","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.05.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}